Bioplatform innovation company Flagship Pioneering announced the launch of Metaphore Biotechnologies, a company harnessing the power of biomimicry and machine learning to unlock the transformative therapeutic potential of functional molecular mimics. And two years into development, Flagship has made an initial commitment of $50 million to advance Metaphore’s MIMiC platform and build its pipeline for patients with autoimmune, metabolic, or oncology indications.
Metaphore’s MIMiC platform imitates and then evolves the function of pharmacophores, the set of essential components that govern interactions between natural bioactive molecules. And the platform systematically isolates a pharmacophore, creating a precise mold of its features that can then be cast into a functional imitation of the original. Plus massively parallel assays are integrated with machine learning-guided engineering to evolve novel mimetic compounds where function, specificity, and selectivity can be explicitly tuned and optimized. These molecular mimics can be designed to modulate previously intractable targets in a programmable way, and be incorporated into any therapeutic modality.
Along with Noubar Afeyan and Lovisa Afzelius, Metaphore’s founding team includes Daniel Acker, Ph.D., Flagship Pioneering Principal, who also serves as Chief Innovation Officer for Metaphore.
Metaphore’s leadership team includes Amanda Kay, Ph.D., Flagship Pioneering Operating Partner and President of Metaphore, former CBO Deep Genomics, and COO Pfizer Inflammation & Immunology; Chaz Hinzman, Ph.D., Flagship Pioneering Associate and Head of Business Operations for Metaphore; and Marcin Paduch, Ph.D., Head of Platform at Metaphore. Plus the company’s advisory team includes Arup Chakraborty, Ph.D., Institute Professor, MIT, Scientific Advisor and Academic Partner, Flagship Pioneering and Founding Steering Committee Member, Ragon Institute; Daniel Lingwood, Ph.D., Associate Professor of Medicine, Harvard Medical School and Core Member, Ragon Institute; Ulrich von Andrian, M.D., Edward Mallinckrodt Jr. Professor of Immunopathology, Microbiology and Immunobiology, Harvard Medical School and Senior Investigator, von Adrian Lab, Boston Children’s Hospital; and Timothy Whitehead, Ph.D., Associate Professor of Chemical and Biological Engineering, University of Colorado Boulder.
KEY QUOTES:
“We asked the question, ‘What if we could engineer therapeutics to trigger the ideal biological response by taking inspiration from mimicry in nature?’ With Metaphore’s MIMiC platform, we pick up where natural evolution left off, designing improved molecular components that make previously intractable targets accessible. We believe this approach has the potential to unlock breakthroughs that outperform today’s drugs and reach patients with few or no therapeutic options.”
— Noubar Afeyan, Ph.D., Founder and CEO of Flagship Pioneering and Co-Founder and Chairman of Metaphore
“Mimicry is one of nature’s oldest tricks, and with Metaphore we adapted it to drug discovery. In nature, organisms gain adaptive advantages by imitating others and, through evolution, these biomimics have been carefully selected and optimized. Similarly, we use our platform to engineer pharmacophores to trigger a desired biological response. The molecular mimics we create can imitate a preexisting interaction or improve upon nature for optimized and programmable function.”
— Lovisa Afzelius, Ph.D., MBA, Origination Partner at Flagship Pioneering and Co-Founder and CEO of Metaphore
